The present invention relates to new pharmaceutical preparations, and especially wherein active constituent includes the human antibodies for being directed to human interleukin I β (IL-1 β), the especially new pharmaceutical formulation of ACZ885 antibody, and pharmaceutical preparation is stablized and without aggregation in storage and delivering.本發明涉及新的藥物製劑,特別是其中活性成分包含針對人白細胞介素Iβ(IL-1β)的人類抗體,特別是ACZ885抗體的新藥物製劑,藥物製劑在貯藏和遞送時是穩定且無聚集的。